ONCOSOL LIMITED
ActiveKey figures
† ONCOSOL LIMITED filed these accounts on paper, so Companies House publishes them only as a scanned image. The figures for the years marked † were read automatically from the scan and kept only where the statements add up (for example net assets equal total equity), but a reading error is still possible — check the original accounts at Companies House.
Like most small UK companies, ONCOSOL LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.
Ratios
2024/25Sector comparison
SIC 20590Where the company stands among the 1,086 active companies whose first SIC code is 20590 (Manufacture of other chemical products n.e.c.).
- JOHNSON MATTHEY PLC£2bn
- ITW LIMITED£1.1bn
- T.J.SMITH AND NEPHEW,LIMITED£446.1m
- RANDOX HOLDINGS LIMITED£235.4m
- ND PHARMA & BIOTECH LTD£211.2m
- RANDOX LABORATORIES LIMITED£163m
- ABGENE LIMITED£118.5m
- SYNTHOMER (UK) LIMITED£115.4m
- LUBRIZOL LIMITED£106.5m
- SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD£85m
Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 1,086. The line on each bar marks the median.
Summary: ONCOSOL LIMITED
What kind of company is it?
ONCOSOL LIMITED is a private limited company registered with Companies House under company number 09904272. It was incorporated on 7 Dec 2015. Its status is active. The registered office is in Northampton (NN7). Its nature of business (SIC 2007) is manufacture of other chemical products n.e.c. (20590), other professional, scientific and technical activities n.e.c. (74909), other business support service activities n.e.c. (82990).
How is the company doing financially?
The latest accounts in the database are for 2024/25 (period ending 31 Mar 2025); the company files small company accounts. Net assets were −£53,281, up 0% on the previous year. Cash at bank and in hand was £16,970. Figures are available for 6 financial years (2020–2024/25).
How does it compare with similar companies?
Compared with 1,086 active companies whose first SIC code is 20590: By net assets it ranks lower than 88% of them (median £272,000). By total assets it ranks lower than 85% of them (median £847,364). By cash it ranks lower than 78% of them (median £208,089). It is younger than 56% of them (median age 13.6 years).
Who runs and controls the company?
The company has 3 current directors. 2 persons with significant control are registered.
When are its next filings due?
The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 22 Apr 2027.
Control structure
Click a box to see its connections.
From the Companies House PSC register: who controls ONCOSOL LIMITED and which UK companies it controls. The register gives bands (for example 25–50% of shares or votes), not exact holdings. A company can be opened only when its number and name match the register; individuals and overseas owners are shown by name only.
Filed accounts2020–2024/25
| 2021 | 2022 | 2022/23 | 2023/24 | 2024/25 † | |
|---|---|---|---|---|---|
| Cash at bank and in hand | 2,533 | 210 | 232 | 16,970 | 16,970 |
| Total assets | — | — | 113,223 | 35,098 | 35,098 |
| Total liabilities | — | — | 137,812 | 88,379 | — |
| Net assets / total equity | -4,371 | -5,344 | -24,589 | -53,281 | -53,281 |
| Average number of employees | 1 | 1 | 0 | 0 | — |
A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.
History
32 events- Financial year 2024/25 endedAccounts: net assets −£53.3k
- Financial year 2023/24 endedAccounts: net assets −£53.3k, 0 employees
- Mohammad Arsalaan KHAN appointedDirector
- Zydus Pharmaceuticals Uk Ltd ceased to be a person with significant control
- Mohammad Arsalaan KHAN resignedSecretary
- Mohammad Arsalaan KHAN resignedDirector
- Amrut NAIK appointedDirector
- Kamlesh Kanubhai PATEL appointedDirector
Earlier events (24)
- Zydus Pharmaceuticals Uk Ltd registered as a person with significant control
- Koanaa Healthcare Limited ceased to be a person with significant control
- Liqmeds Lifecare Limited ceased to be a person with significant control
- Financial year 2022/23 endedAccounts: net assets −£24.6k, 0 employees
- Liqmeds Lifecare Limited registered as a person with significant control
- Koanaa Healthcare Limited registered as a person with significant control
- Financial year 2022 endedAccounts: net assets −£5,344, 1 employee
- Koanaa Healthcare Limited registered as a person with significant control
- Liqmeds Lifecare Limited registered as a person with significant control
- Mr Mohammad Arsalaan Khan ceased to be a person with significant control
- Financial year 2021 endedAccounts: net assets −£4,371, 1 employee
- Financial year 2020 endedAccounts: net assets −£2,793, 1 employee
- Name changed to ONCOSOL LIMITEDPreviously ASA LIFE UK LTD
- Nisha Manish KHEMKA resignedDirector
- Alok MISHRA resignedDirector
- Nisha Manish KHEMKA appointedDirector
- Alok MISHRA appointedDirector
- Name changed to ASA LIFE UK LTDPreviously ONCOSOL LIMITED
- Mr Mohammad Arsalaan Khan registered as a person with significant control
- Michael DUKE resignedDirector
- Mohammad Arsalaan KHAN appointedSecretary
- Michael DUKE appointedDirector
- Mohammad Arsalaan KHAN appointedDirector
- Company incorporatedPrivate limited company
Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current and former persons with significant control, and the end of each financial year with figures in the database.